David J Bean
Overview
Explore the profile of David J Bean including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
196
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bean D, Liang Y, Sagar M
bioRxiv
. 2024 Nov;
PMID: 39484477
Recent documented infection with an endemic coronavirus (eCoV) associates with less severe coronavirus disease 2019 (COVID-19), yet the immune mechanism behind this protection has not been fully explored. We measured...
2.
Bean D, Monroe J, Liang Y, Borberg E, Senussi Y, Swank Z, et al.
Sci Transl Med
. 2024 Jun;
16(751):eado7588.
PMID: 38865483
Immune responses from prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and COVID-19 vaccination mitigate disease severity, but they do not fully prevent subsequent infections, especially from genetically divergent...
3.
Joshi V, Claiborne D, Pack M, Power K, Newman R, Batorsky R, et al.
J Virol
. 2024 Feb;
98(3):e0172023.
PMID: 38412036
The rational design of HIV-1 immunogens to trigger the development of broadly neutralizing antibodies (bNAbs) requires understanding the viral evolutionary pathways influencing this process. An acute HIV-1-infected individual exhibiting >50%...
4.
Bean D, Monroe J, Liang Y, Borberg E, Senussi Y, Swank Z, et al.
bioRxiv
. 2023 Nov;
PMID: 37961343
Immune responses from prior SARS-CoV-2 infection and COVID-19 vaccination do not prevent re-infections and may not protect against future novel coronaviruses (CoVs). We examined the incidence of and immune differences...
5.
Bean D, Monroe J, Turcinovic J, Moreau Y, Connor J, Sagar M
Clin Infect Dis
. 2021 Nov;
75(1):e208-e215.
PMID: 34755830
Background: The factors associated with severe acute respiratory coronavirus 2 (SARS-CoV-2) reinfection remain poorly defined. Methods: We identified patients with SARS-CoV-2 infection and at least 1 repeat reverse transcription polymerase...
6.
Bean D, Sagar M
J Clin Invest
. 2021 Nov;
131(24).
PMID: 34752421
The increasing frequency of pathogenic coronaviruses in the human population has raised public health concerns about possible future pandemics. It is critical to understand whether immune responses to the current...
7.
Tully D, Hahn J, Bean D, Evans J, Morris M, Page K, et al.
Clin Infect Dis
. 2021 Aug;
74(6):993-1003.
PMID: 34448809
Background: The current opioid epidemic across the United States has fueled a surge in the rate of new hepatitis C virus (HCV) infections among young persons who inject drugs (PWIDs)....
8.
Tonnerre P, Wolski D, Subudhi S, Aljabban J, Hoogeveen R, Damasio M, et al.
Nat Immunol
. 2021 Jul;
22(8):1030-1041.
PMID: 34312544
T cell exhaustion is associated with failure to clear chronic infections and malignant cells. Defining the molecular mechanisms of T cell exhaustion and reinvigoration is essential to improving immunotherapeutic modalities....
9.
Hochstatter K, Tully D, Power K, Koepke R, Akhtar W, Prieve A, et al.
Emerg Infect Dis
. 2021 Jan;
27(2):480-489.
PMID: 33496239
Ending the hepatitis C virus (HCV) epidemic requires stopping transmission among networks of persons who inject drugs. Identifying transmission networks by using genomic epidemiology may inform community responses that can...
10.
Hahn J, Tully D, Evans J, Morris M, Briceno A, Bean D, et al.
Open Forum Infect Dis
. 2019 May;
6(4):ofz125.
PMID: 31041340
Background: Hepatitis C virus (HCV), a major cause of morbidity and mortality, is common and rising among young persons who inject drugs (PWID). Reducing the level of viremia may be...